ZyVersa Therapeutics to Participate in a Fireside Chat at :

CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease,...

Related Keywords

Stephenc Glover , Casey Mcdonald , Dave Schemelia , Ceo Stephenc Glover , Tiberend Strategic Advisors Inc , Securities Exchange , Zyversa Therapeutics Inc , Nasdaq , Cholesterol Efflux Mediator , Versa Therapeutics , Chief Executive Officer , Annual Oppenheimer Healthcare Conference , Annual Oppenheimer Healthcare , Cholesterol Efflux , Zyversa Therapeutics , Securities Exchange Act , Private Securities Litigation Reform Act , Strategic Advisors , Nasdaq Zvsa , Yversa , Renal Disease , Nflammasomes , Nflammasome Inhibitors , Usgs , Alport Syndrome , Diabetic Kidney Disease , Investors ,